2月4日上午，市交控集团到高新区就产业发展、政策对接、项目合作等核心议题开展交流座谈。 座谈会上就双方聚焦的招标代理、供应链建设、临港产业协作、片区开发、规划设计、工程建设、物业 服务等多个领域合作等方面提出了针对性指导意见，明确表示将全力支持双方合作，在政策衔接、要素 保障、流程优化等方面做好服务，为合作项目落地保驾护航，确保早日取得实质性成果，实现区域发展 与企业发展同频共振、互利共赢。 市交控集团详细介绍了集团公司及下属企业在转型升级和快速发展方面取得的成绩，。并表示将认真梳 理此次座谈中高新区提出的指导意见与建议，结合集团"十五五"发展规划，进一步优化各领域合作方 案、细化实施路径、强化责任落实，主动对接高新区发展需求，全力以赴推动各意向合作项目落地见 效。同时，将充分发挥自身在交通基础设施建设、产业投资运营等方面的优势，深度融入高新区发展大 局，在更多领域拓展合作空间，推动双方资源互补、优势叠加，实现共同发展。 （来源：安庆新闻网） 转自：安庆新闻网 ...

Group 1 - The core viewpoint of the article is that 中新集团 is focusing on the embodied intelligence industry by creating a comprehensive model that includes "carrier + fund + platform + cultivation + ecosystem" [1] - The company is actively negotiating and establishing partnerships with multiple enterprises in the embodied intelligence sector to promote industrial clustering [1] - The goal is to assist Suzhou Industrial Park in becoming a nationally influential hub for the development of the embodied intelligence robotics industry [1]

Group 1 - The issuance of bonds "25金丰V1", "25金丰V2", "25泰华02", and "25泰华03" was successfully completed, with a total scale of 5.8 billion yuan for the rural revitalization bonds [1] - The issuer, Jinfeng Industrial Development Investment Group, plays a significant role in the regional economic development, focusing on the production and sales of aluminum fluoride and water supply [1] - The bonds had strong subscription rates, with "25金丰V1" having a subscription multiple of 5.86 times and "25金丰V2" at 4.13 times [1] Group 2 - Taizhou Huaxin Pharmaceutical Investment Co., Ltd. focuses on the integration of investment, construction, and operation in the health industry, with a main business in pharmaceutical health, infrastructure development, and urban commercial services [2] - The company aims to create a comprehensive biopharmaceutical industry chain in the Yangtze River Delta region, encompassing various functions such as drug research, exhibition trading, production, and healthcare [2] - Minsheng Securities actively assisted the issuer in communication with regulatory authorities, aiming to create a low-cost and efficient financing environment for the issuer [2]